ASXL1 and chronic myelogenous leukemia, BCR-ABL1 positive: This is also consistent with clinical data that suggest that CML patients whose normal and leukemic cells share mutations in genes such as TET2 and ASXL1, which are known to increase stem cell self-renewal (Steensma, 2018), tend to have inferior outcomes under TKI therapy (Kim et al., 2017; Marum et al., 2017).